COSMO PHARMACEUTICALS NV (C43.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:C43 - NL0011832936 - Common Stock
48.8 EUR
-1.2 (-2.4%)
C43 gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. C43 gets an excellent profitability rating and is at the same time showing great financial health properties. C43 is evaluated to be cheap and growing strongly. This does not happen too often! C43 also has an excellent dividend rating. With these ratings, C43 could be worth investigating further for value and dividend and growth and quality investing!.
1. Profitability
1.1 Basic Checks
C43 had positive earnings in the past year.
C43 had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: C43 reported negative net income in multiple years.
In the past 5 years C43 always reported a positive cash flow from operatings.
1.2 Ratios
C43 has a Return On Assets of 20.60%. This is amongst the best in the industry. C43 outperforms 94.23% of its industry peers.
With a decent Return On Equity value of 26.74%, C43 is doing good in the industry, outperforming 76.92% of the companies in the same industry.
C43 has a better Return On Invested Capital (21.60%) than 88.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROIC | 21.6% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
C43 has a better Profit Margin (49.94%) than 98.08% of its industry peers.
C43's Profit Margin has improved in the last couple of years.
C43 has a Operating Margin of 55.81%. This is amongst the best in the industry. C43 outperforms 100.00% of its industry peers.
C43's Operating Margin has improved in the last couple of years.
The Gross Margin of C43 (83.00%) is better than 86.54% of its industry peers.
In the last couple of years the Gross Margin of C43 has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% |
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so C43 is creating value.
The number of shares outstanding for C43 has been reduced compared to 1 year ago.
Compared to 5 years ago, C43 has more shares outstanding
Compared to 1 year ago, C43 has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.80 indicates that C43 is not in any danger for bankruptcy at the moment.
The Altman-Z score of C43 (5.80) is better than 90.38% of its industry peers.
The Debt to FCF ratio of C43 is 0.01, which is an excellent value as it means it would take C43, only 0.01 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.01, C43 belongs to the top of the industry, outperforming 98.08% of the companies in the same industry.
C43 has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, C43 belongs to the top of the industry, outperforming 94.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Altman-Z | 5.8 |
ROIC/WACC2.81
WACC7.68%
2.3 Liquidity
C43 has a Current Ratio of 4.19. This indicates that C43 is financially healthy and has no problem in meeting its short term obligations.
C43 has a better Current ratio (4.19) than 96.15% of its industry peers.
A Quick Ratio of 3.91 indicates that C43 has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.91, C43 belongs to the best of the industry, outperforming 96.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 1315.29% over the past year.
Measured over the past years, C43 shows a very strong growth in Earnings Per Share. The EPS has been growing by 85.20% on average per year.
Looking at the last year, C43 shows a very strong growth in Revenue. The Revenue has grown by 187.55%.
C43 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.68% yearly.
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
3.2 Future
C43 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.02% yearly.
C43 is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.67% yearly.
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 5.98, the valuation of C43 can be described as very cheap.
92.31% of the companies in the same industry are more expensive than C43, based on the Price/Earnings ratio.
C43 is valuated cheaply when we compare the Price/Earnings ratio to 26.31, which is the current average of the S&P500 Index.
C43 is valuated reasonably with a Price/Forward Earnings ratio of 8.09.
C43's Price/Forward Earnings ratio is rather cheap when compared to the industry. C43 is cheaper than 84.62% of the companies in the same industry.
C43 is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 |
4.2 Price Multiples
C43's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. C43 is cheaper than 96.15% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, C43 is valued cheaper than 94.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.46 | ||
| EV/EBITDA | 3.83 |
4.3 Compensation for Growth
The excellent profitability rating of C43 may justify a higher PE ratio.
C43's earnings are expected to decrease with -27.68% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
5. Dividend
5.1 Amount
C43 has a Yearly Dividend Yield of 3.85%. Purely for dividend investing, there may be better candidates out there.
The stock price of C43 dropped by -28.24% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
C43's Dividend Yield is a higher than the industry average which is at 2.86.
C43's Dividend Yield is rather good when compared to the S&P500 average which is at 2.34.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
5.2 History
On average, the dividend of C43 grows each year by 7.41%, which is quite nice.
Dividend Growth(5Y)7.41%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
24.09% of the earnings are spent on dividend by C43. This is a low number and sustainable payout ratio.
The dividend of C43 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP24.09%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
FRA:C43 (4/29/2025, 7:00:00 PM)
48.8
-1.2 (-2.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.98%
Inst Owner ChangeN/A
Ins Owners38.78%
Ins Owner ChangeN/A
Market Cap855.95M
Revenue(TTM)266.79M
Net Income(TTM)133.24M
Analysts84
Price Target104.72 (114.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
Yearly Dividend2
Dividend Growth(5Y)7.41%
DP24.09%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.87%
Revenue NY rev (3m)-12.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 | ||
| P/S | 3.21 | ||
| P/FCF | 5.46 | ||
| P/OCF | 5.27 | ||
| P/B | 1.72 | ||
| P/tB | 6.01 | ||
| EV/EBITDA | 3.83 |
EPS(TTM)8.16
EY16.72%
EPS(NY)6.03
Fwd EY12.36%
FCF(TTM)8.94
FCFY18.31%
OCF(TTM)9.26
OCFY18.97%
SpS15.21
BVpS28.41
TBVpS8.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROCE | 24.88% | ||
| ROIC | 21.6% | ||
| ROICexc | 28.38% | ||
| ROICexgc | 129.8% | ||
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% | ||
| FCFM | 58.76% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y181.33%
ROICexgc growth 5YN/A
ROICexc growth 3Y154.84%
ROICexc growth 5YN/A
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 46.02% | ||
| Cap/Sales | 2.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 100.77% | ||
| Profit Quality | 117.65% | ||
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z | 5.8 |
F-Score8
WACC7.68%
ROIC/WACC2.81
Cap/Depr(3y)45.29%
Cap/Depr(5y)77.05%
Cap/Sales(3y)4.67%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
EBIT growth 1Y8040.37%
EBIT growth 3Y137.59%
EBIT growth 5YN/A
EBIT Next Year-33.52%
EBIT Next 3Y-14.79%
EBIT Next 5Y28.59%
FCF growth 1Y756.04%
FCF growth 3Y236.69%
FCF growth 5YN/A
OCF growth 1Y615.22%
OCF growth 3Y134.4%
OCF growth 5YN/A
COSMO PHARMACEUTICALS NV / C43.DE FAQ
What is the ChartMill fundamental rating of COSMO PHARMACEUTICALS NV (C43.DE) stock?
ChartMill assigns a fundamental rating of 9 / 10 to C43.DE.
What is the valuation status of COSMO PHARMACEUTICALS NV (C43.DE) stock?
ChartMill assigns a valuation rating of 8 / 10 to COSMO PHARMACEUTICALS NV (C43.DE). This can be considered as Undervalued.
How profitable is COSMO PHARMACEUTICALS NV (C43.DE) stock?
COSMO PHARMACEUTICALS NV (C43.DE) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for C43 stock?
The Price/Earnings (PE) ratio for COSMO PHARMACEUTICALS NV (C43.DE) is 5.98 and the Price/Book (PB) ratio is 1.72.
Can you provide the financial health for C43 stock?
The financial health rating of COSMO PHARMACEUTICALS NV (C43.DE) is 9 / 10.